BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript

Operator

Hello, everyone. Thank you for joining us, and welcome to the BioMarin Third Quarter 2026 Conference Call. [Operator Instructions]

I will now hand the call over to BioMarin’s Head of Investor Relations, Traci McCarty. Please go ahead.

Traci McCarty
Group Vice President

Thank you, operator. To remind you, this nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin’s financial performance, commercial products and potential future products in different areas of therapeutic research and development.

Results may differ materially depending on the progress of BioMarin’s product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission, such as 10-Q, 10-K and 8-K reports.

In addition, we will use non-GAAP financial measures as defined in Regulation G during the call today. These non-GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with U.S. GAAP, and you can find the related reconciliations to U.S. GAAP in the earnings release and earnings